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A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel 
ThyroSeq v.2
Tiroid Kanser Genomiğinin Güncel Klinik Atlası: ThyroSeq v.2 Yeni Jenerasyon 
Dizinleme Paneli
Abstract
The next-generation sequencing technology allows high out-put genomic analysis. An innovative assay in thyroid cancer, 
ThyroSeq® was developed for targeted mutation detection by next generation sequencing technology in fine needle 
aspiration and tissue samples. ThyroSeq v.2 next generation sequencing panel offers simultaneous sequencing and detection 
in >1000 hotspots of 14 thyroid cancer-related genes and for 42 types of gene fusions known to occur in thyroid cancer. 
ThyroSeq is being increasingly used to further narrow the indeterminate category defined by cytology for thyroid nodules. 
From a surgical perspective, genomic profiling also provides prognostic and predictive information and closely relates to 
determination of surgical strategy. Both the genomic analysis technology and the informatics for the cancer genome data 
base are rapidly developing. In this paper, we have gathered existing information on the thyroid cancer-related genes involved 
in the initiation and progression of thyroid cancer. Our goal is to assemble a glossary for the current ThyroSeq genomic panel 
that can help elucidate the role genomics play in thyroid cancer oncogenesis. 
Keywords: Thyroid cancer, next generation sequencing, ThyroSeq
Öz
Tiroid nodüllerinde kanser teşhisi ve tiroid kanserlerinin prognostik değerlendirilmesi için geliştirilmiş en güncel yöntem DNA 
dizinleme teknolojisine dayalı ThyroSeq® testidir. Bu test ince iğne aspirasyon materyalinde genetik profilleme yaparak tiroid 
kanserinin tetiklenmesinde ve gelişmesinde rol alan mutasyon ve genetik değişiklikleri tespit etmektedir. Bu makalede bu 
test ile tespit edilebilen genetik değişikliklere konu olan genlerin yapı ve fonksiyonlarını kısaca tanımlıyoruz. Tiroid kanseri 
onkogenezine bir ölçüde ışık tutan bu test için sözlük görevi tutan bir makale sunulmaktadır. 
Anahtar kelimeler: Tiroid kanseri, yeni jenerasyon dizinleme, ThyroSeq
©Copyright 2017 by Turkish Society of Nuclear Medicine
Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.
Introduction
Thyroid nodules are prevalent in the general population. 
Most thyroid nodules are benign and the clinical challenge 
is to accurately identify those nodules that are malignant 
and need to be surgically removed (1). Moreover, the extent 
of initial surgical treatment requires better understanding 
of particular tumor biology beyond conventional 
definitions. Molecular pathology is the new paradigm 
in cancer diagnosis and prognostication. Thyroid cancer 
develops and progresses through accumulation of genetic 
alterations, which does serve as important diagnostic, 
prognostic, and predictive biological markers (2). Next-
generation sequencing technology allows high out-put 
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genomic analysis. An innovative assay in thyroid cancer - 
ThyroSeq® - was developed for targeted mutation detection 
by next generation sequencing technology in fine needle 
aspiration and tissue samples. ThyroSeq v.2 next generation 
sequencing panel offers simultaneous sequencing and 
detection in >1000 hotspots of 14 thyroid cancer-related 
genes and for 42 types of gene fusions known to occur 
in thyroid cancer (3). ThyroSeq is being increasingly used 
to further narrow the indeterminate category defined by 
cytology for thyroid nodules. From a surgical perspective, 
understandably this provides prognostic and predictive 
information as it relates to determination of surgical 
strategy. Both the genomic analysis technology and the 
data collection for the cancer genome atlas are rapidly 
developing.
This paper reviews basic genomic information on 23 
thyroid cancer-related genes involved in thyroid cancer. 
We have detailed information in regards to the location, 
and function of these genes in normal thyroid cells. We 
also report gathered information as to the consequences 
mutations to these 23 genes can have on thyroid cancer 
initiation and progression. Our goal is to provide a detailed 
glossary for ThyroSeq mutation panel. 
Molecular Markers of ThyroSeq Next-Generation 
Sequencing Panel
B-RAF
The B-RAF gene, located on chromosome 7q34, encodes 
B-RAF serine-threonine kinase, which functions as an 
intracellular effector of the RAS/MAPK signaling cascade 
(Figure 1). This is one of the three isoforms of the RAF 
serine-threonine kinase and the predominant isoform found 
Figure 1. MAPK/ERK pathway
*This pathway begins with a mitogenic stimulus binding to a receptor tyrosine kinase, activating it. This triggers a cascade of protein activation, beginning with RAS and 
culminating with ERK. Once ERK is phosphorylated, it enters the nucleus and influences transcription, increasing expression of tumor-promoting genes and decreasing 
expression of tumor-suppressing genes. MAPK signaling can also be stimulated by genetic alterations in proteins RET and NTRK
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in thyroid follicular cells. In wild-type forms of this gene, 
the B-RAF protein is activated through binding of a RAS-
GTP protein complex with the B-RAF’s RAS binding domain 
along with simultaneous conformational changes in the 
protein. Once activated, the B-RAF protein phosphorylates 
the next protein in the signal cascade-MEK and ERK. The 
protein’s function contributes to the RAS/MAPK pathway’s 
role in cell proliferation, migration, and differentiation (4,5).
The most common B-RAF mutation found in thyroid 
carcinomas is a point mutation at residue 600 involving 
a substitution from valine to glutamate (V600E). This 
mutation results in the constitutive activation of the B-RAF 
protein and subsequently the RAS/MAPK pathway. The 
activation of the B-RAF protein seems to be caused by a 
disruption of the hydrophobic interactions between its 
activation loop and the ATP binding site. In wild-type B-RAF, 
these hydrophobic interactions help maintain the protein in 
an inactive conformation. When disrupted, B-RAF remains 
in an active, catalytic conformation. This results in the 
constitutive phosphorylation of its downstream targets (4).
The B-RAF V600E point mutation is most prevalent in 
papillary thyroid carcinomas (PTC)-the most common form 
of well differentiated thyroid carcinoma-found in 45% of 
PTC cases. Though it is rare in follicular variants of thyroid 
carcinoma, B-RAF is an ideal genetic marker for use in a 
thyroid cancer sequencing panel. It is found in all forms of 
thyroid carcinoma and seems to play a very important role 
early in tumorigenesis as a driver mutation (4,5,6).
RAS
The RAS genes consist of a family of highly homologous 
isoforms: K-RAS, N-RAS, and H-RAS. Located on 
chromosomes 12p12.1, 11p5.5, and 1p13.1 respectively, all 
three genes encode G-proteins located on the inner surface 
of the cell membrane. These proteins help convey signals 
from receptor tyrosine kinases (RTKs) to the pathways RAS 
regulates: RAS/MAPK and PI3K/AKT signaling cascades 
(Figure 2). Once bound to GTP, the RAS proteins proceed 
to activate the RAS/MAPK pathway. The RAS-GTP complex 
quickly becomes inactive as a result of the protein’s innate 
GTPase activity (7).
Point mutations in the RAS gene are the most common 
mutations. Mutations in codons 12 and 13 lead to an 
increased affinity for GTP. Mutations in codon 61 lead to 
inactivation of the RAS protein’s innate GTPase function. 
Overall, these mutations result in the constitutive 
activation of the RAS protein and thus the activation of 
the downstream signaling pathways it regulates, a critical 
step in thyroid tumorigenesis. Thyroid carcinoma has been 
associated with mutations in all three isoforms of the 
RAS genes, though it seems the more prevalent mutated 
isoform is that of N-RAS. However, the actual pattern of 
isoform frequencies in thyroid carcinoma remains unclear 
(4,7).
RAS mutations occur with variable frequency in all types 
of thyroid follicular-derived tumors. RAS point mutations 
are most common in follicular thyroid carcinoma (FTC), 
occurring in 40-50% of tumors, as well as in poorly 
differentiated and anaplastic thyroid carcinoma (PDC and 
ATC). It is more infrequent in PTCs, occurring in about 10% 
of tumors. The prevalence of RAS mutations in thyroid 
carcinoma make it a viable genetic marker as well as a 
useful prognostic tool, given that, studies suggest it may 
increase the potential for malignant transformation and 
tumor progression (7).
CTNNB1
The CTNNB1 gene, located on chromosome 3p21, encodes 
a cytoplasmic protein known as β-catenin. This protein 
plays several important roles in the cell. It is involved in 
E-cadherin mediated cell to cell adhesion, found primarily 
in adherens junctions. It is also an intermediate in the Wnt 
signaling pathway. Once activated by proteins upstream 
in the pathway, β-catenin is able to accumulate in the 
cytoplasm and eventually is translocated into the nucleus. 
In the nucleus, the protein works with T-cell factor/
lymphoid enhancing factor (TCF/LEF) to modulate gene 
expression (8,9).
When β-catenin is not activated, free cytoplasmic levels 
are kept low through ubiquitin-proteasome degradation 
(Figure 3). However, point mutations in exon 3 of CTNNB1 
confer added stability to the protein and thus inhibit the 
degradation of β-catenin. This results in the accumulation 
and localization of β-catenin in the cytoplasm and nucleus 
of the cell and the constitutive activation of its targeted 
genes (ex: Cyclin D1, C-MYC, C-JUN) (8,10,11).
Mutations in CTNNB1 are most commonly found in PDC 
and ATC but not in well differentiated forms. It is typically 
described as a late event in thyroid cancer progression, but 
dysregulation of β-catenin has been shown to contribute to 
tumor proliferation (10,11).
CTNNB1 can serve as a useful marker for PDC and ATC. 
Its involvement in the Wnt pathway contributes to its 
viability as a marker, given this pathway is constitutively 
active in 50% of PDC and ATC and it is involved in the 
dedifferentiation process of thyroid carcinoma (Figure 4) 
(10). This gene is thus a useful diagnostic marker as well as 
prognostic tool to determine the progression of the cancer 
and its propensity to spread. 
NTRK1 
The NTRK1 gene, which is located on chromosome 1q21-
22, encodes the neurotrophic RTK-1, also known as TrkA. It 
is a high affinity receptor for nerve growth factor-β (NFG-β) 
that provides instructions for the growth and development 
of nerve cells. It also induces the proliferation of a number of 
cell types, such as lymphocytes and keratinocytes. Once it is 
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bound to NFG-β, NTRK1 dimerizes and autophosphorylates 
its five tyrosine residues, which then act as binding sites for 
several target proteins such as RAS and PI3K. By activating 
these proteins, NTRK1 subsequently activates the RAS/
MAPK and PI3K/AKT signaling cascades, thus mediating 
NGF effects on the proliferation and differentiation of cells 
(12,13).
Mutations in the NTRK1 gene are frequently found in PTC. 
These mutations involve chromosomal rearrangements 
between NTRK1 and at least three other identified genes: 
TPM3, TPR, and TFG. The chimeric oncogenes that are 
formed (TRK oncogenes) encode constitutively active RTKs. 
It remains active due to the fact that its kinase domain 
and the tyrosine binding sites are preserved in the chimeric 
oncogene. The only portion that is lost is a portion of 
its extracellular domain. It seems that the extracellular 
domain may contain important regulatory elements. This 
provides constant activation of the protein signals for cell 
proliferation, contributing to PTC (12,13).
About 60% of PTC carry chimeric oncogenes created 
through chromosomal rearrangement. Though RET 
rearrangement and not NTRK1 is the most prevalent 
chimeric oncogene detected in PTC, thyroid epithelium 
seems to have a propensity for chromosomal 
rearrangements. That fact, along with NTRK1 association 
with pathways implicated in thyroid carcinoma (RAS/
MAPK and PI3K/AKT) make this gene a viable marker for 
diagnostic and prognostic purposes. Nevertheless, further 
investigation is necessary to better understand its role in 
thyroid carcinogenesis (13,14).
Figure 2. PI3K/AKT pathway
*The pathway begins with an extracellular stimuli activating a receptor tyrosine kinase, triggering the activation of RAS followed by PI3K. Activated PI3K catalyzes the conversion 
of phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a step that is regulated by PTEN. PIP3 activates the 3-phosphoinositide-
dependent protein kinase 1, which targets and phosphorylates AKT. Phosphorylated AKT then enters the nucleus, where it increases the expression of tumor-promoting genes. 
Activated AKT also produces changes in the cytoplasm by activating mTOR and thus promoting translation. AKT can also phosphorylate glycogen synthase kinase 3-β (GSK3-β), 
inactivating the protein. GSK3-β inhibition results in a concomitant stimulation of β-catenin, allowing it to enter the nucleus and increase expression of tumor-promoting genes
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NTRK3
Another member of the neurotrophic tyrosine receptor 
kinase family, NTRK3 encodes a RTK with a high affinity for its 
ligand neurotrophin-3. The gene is located on chromosome 
15q25. Once bound, NTRK3 autophosphorylates and 
proceeds to phosphorylate target proteins primarily involved 
in the RAS/MAPK and PI3K/AKT signaling pathways. 
Primarily expressed in the central nervous system, NTRK3 
is involved in cell proliferation and differentiation as well as 
neuronal cell processes (14,15).
The mutation of NTRK3 observed in thyroid carcinomas 
is a chromosomal rearrangement involving ETV6, a gene 
encoding a transcription factor from the ETS transcription 
factor family. This particular oncogenic fusion involves the 
fusion of exons 1-4, the SAM domain, of ETV6 and exons 
12-18, the tyrosine kinase domain, of NTRK3. This results 
in the constitutive activation of the RTK. It is this constant 
activation that contributes to thyroid carcinogenesis 
(15,16).
Chromosomal rearrangements of the NTRK genes are 
uncommon in sporadic PTC, only occurring in about 2% 
of cases. However, there is higher prevalence of these 
chimeric oncogenes in pediatric and radiation-related PTC, 
with the majority of ETV6-NTRK3 fusions demonstrating 
the follicular variant of PTC. Mutations resulting in RAS/
MAPK activation in radiation-related PTC tend to differ 
from those found in sporadic PTC as there tends to be 
more chromosomal rearrangements than point mutations 
(15,16).
RET 
The RET gene is a proto-oncogene that is highly expressed 
in parafollicular C-cells. Located on chromosome 10q11.2, 
this gene encodes a RTK that is involved in the RAS/MAPK 
Figure 3. CTNNB1/TERT signaling
*Dysregulation of telomerase is an almost universal feature of cancer, either through genetic amplification of the gene’s own locus or through crosstalk activity with other 
signaling pathways. In this pathway mutations to the promoter site of TERT (C228T and C250T) increase the transcription of TERT through the creation of consensus binding 
sites for ETS transcription factors. Constitutive action of the MAPK pathway due to B-RAF or RAS mutations leads to upregulation of TERT from ETS transcription binding activity. 
TERT also possess a role as a transcriptional modulator of the Wnt-β-catenin signaling pathway. Wnt stimulation at the plasma membrane leads to increased levels of β-catenin 
in the cytoplasm, and translocation to the nucleus. In the nucleus β-catenin forms a complex with TERT and the Wnt transcription factor BRG1. Once formed this complex binds 
to the promoters of Wnt target genes regulating the expression of these oncogenes
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signaling pathway. The RET protein responds to signals 
from the cell’s environment and then proceeds to activate 
itself through autophosphorylation. Once activated, the 
RET protein elicits changes within the cell often involving 
cell proliferation and development (4,17).
Chromosomal rearrangements involving RET represents one of 
the most common causes of PTC. At least 11 rearrangement 
variants have been isolated but the most common translocations 
are RET/PTC1 and RET/PTC3. The aforementioned 
rearrangements are intrachromosomal paracentric inversions 
and account for the vast majority of variants found in PTC. 
These rearrangements result in a constitutively active RET 
protein, leading to activation of the RAS/MAPK pathway and 
driving thyroid carcinogenesis (17,18).
The RET/PTC1 rearrangement involves interaction between 
RET and the H4 gene. This particular rearrangement 
is the dominant type in sporadic PTCs. The RET/PTC3 
rearrangement involves interaction between RET and the 
ELE1 gene. This particular rearrangement is the dominant 
type in radiation-related PTCs, which tend to be more 
aggressive and exhibit a higher frequency of chromosomal 
rearrangements (4,17).
AKT1 
AKT1 codes for the AKT1 kinase, one member of a 
family of homologous isoforms. Located on chromosome 
14q32.322, AKT1 kinase helps regulate cell growth and 
survival as well as the process of apoptosis, mainly through 
interaction with signaling pathways like PI3K/AKT. The 
protein contains a pleckstrin homology domain, making 
it a target for phospholipids generated by PI3K activity. 
Once activated through phosphorylation, AKT1 binds to 
chaperone proteins and proceeds to phosphorylate its 
downstream effectors. Through this pathway, activated 
AKT1 is able to inhibit apoptosis and induce cell growth in 
thyroid cells (19).
Activation of AKT1 is known to promote thyroid tumorigenesis 
in Cowden’s syndrome (CS). It is the overexpression and 
overactivation of AKT1, rather than mutation of the AKT1 
gene, that contributes to the pathogenesis of sporadic 
thyroid cancers, particularly in follicular thyroid cancers (FTC). 
In FTCs, activation of AKT1 kinase and the localization of 
the protein in the nucleus promotes the PI3K/AKT pathway, 
contributing to tumor invasion and metastasis. It seems 
that overexpression of AKT1 is capable of promoting cell 
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Figure 4. Thyroid hormone signaling
*Follicular cells contain thyroid stimulating hormone receptors (TSHR). Once bound to the hormone TSH, this G-protein coupled receptor generates the second messenger 
cyclic AMP. This second messenger activates protein kinases that trigger signal cascades responsible for thyroid cell proliferation and function. TSH stimulation of TSHR also 
leads to iodide transport into the cell via the sodium iodide symporter. This iodide is oxidized and then bound to tyrosine residues on thyroglobulin (TG), a process catalyzed by 
thyroperoxidase. This primed form of TG can then be cleaved through proteolysis in the cell to generate the thyroid hormones T3 and T4
proliferation, sensitization to TSH, and inhibiting apoptosis, 
but it is not sufficient to transform thyroid cells by itself 
(19,20). 
This alteration in AKT1 occurs in about 15% of metastatic 
thyroid cancers, while also occurring in small fractions 
of ATCs and FTCs. Studies have shown that there is 
an association between AKT1 activation and tumor 
aggressiveness. This association with metastasis in thyroid 
carcinoma was found in both PTC and FTC. However, the 
aggressiveness seen is likely attributed to a combination of 
genetic alterations rather than solely on dysregulation of 
AKT1 activity (19,20,21). 
TERT 
The TERT gene, located on chromosome 5p15.33, encodes 
the protein telomerase reverse transcriptase. It is the 
catalytic subunit of the telomerase enzyme and determines 
telomerase activity. The TERT subunit associates with a RNA 
component TERC as well as additional components to form 
the telomerase enzyme. Telomerase serves an important 
role in synthesizing and maintaining telomeres, which 
helps prolong the life of cells in the body. When telomeres 
become too short, apoptosis is triggered in the cell. As a 
result, telomerase activity is highly regulated and expressed 
at very low levels in most tissues in the body (22).
Dysregulation of telomerase is an almost universal feature 
of cancer, with over 90% exhibiting overexpression of the 
enzyme. This imparts cancer cells with an infinite capability 
to divide. The up-regulation of TERT that is seen could be the 
result of epigenetic deregulation or genetic amplification 
of the gene’s locus (Figure 3). Other factors contributing 
to the dysregulation of TERT expression involve changes 
in transcription factors that target the TERT gene. Such 
factors include TP53 and the ETS transcription factors. 
Both are disrupted in thyroid carcinoma as TP53 is often 
mutated and ETS transcription factors are stimulated 
by several oncogenes including RAS. These associations 
indicate a relationship between an up-regulation of TERT 
expression and the transformation of thyroid cells. One 
recently discovered mechanism has been mutations in the 
TERT promoter, the most important regulatory element of 
telomerase activity (22,23).
These promoter mutations, C228T and C250T, seem to 
increase the transcription of TERT, likely through the 
creation of consensus binding sites for ETS transcription 
factors. Promoter mutation C228T is the most common 
one found in thyroid carcinoma with no overlaps reported 
in the mutations. There seems to be a higher prevalence 
of TERT promoter mutations in more advanced forms of 
thyroid carcinoma like ATC. Studies have shown a strong 
association between TERT promoter mutations and B-RAF 
or RAS mutations as well. The evidence uncovered so 
far shows that mutations in the TERT promoter seems to 
represent a late stage genetic event in tumorigenesis as 
well as an indicator of aggressiveness given its prevalence 
in ATC (24,25). 
GNAS 
The GNAS gene provides instructions for the stimulatory 
α-subunit of heterotrimeric G protein complexes. The 
gene is located on chromosome 20q13.3. This subunit 
stimulates the activity of adenylate cyclase and controls 
the production of several hormones that help regulate 
the activity of the endocrine glands such as the thyroid 
gland. Mutations in GNAS are often detected at codons 
201 and 227. These mutations result in the constitutive 
activation by impairing GTP hydrolysis. This in turn results 
in the constitutive activation of the cyclic AMP (cAMP) 
cascade. The increase in cAMP levels results in thyroid cell 
proliferation and increased thyroid hormone production. 
Despite this disruption in function, these mutations are 
almost never malignant (20,26).
Activating mutations of GNAS has been shown to 
overactivate thyroid stimulating hormone receptor (TSHR) 
signaling. This often leads to benign, hyperfunctional 
follicular thyroid adenomas (FTAs). Mutation of GNAS is 
also the main cause for autonomously functioning thyroid 
nodules. Studies show that mutations in GNAS resulting 
in overactivation of the G protein alpha subunit leads to a 
hyperfunctioning thyroid. Serving as a potential marker for 
benign thyroid nodules, GNAS does not seem to serve as a 
driver of thyroid carcinogenesis. However, it seems likely that 
this disruption in thyroid function in conjunction with other 
genetic alterations plays a role in thyroid carcinoma (26).
PIK3CA 
PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha, is a gene located on chromosome 
3q26.3. It encodes the p110 alpha subunit of the PI3K 
kinase. This particular subunit is the catalytic subunit and 
is responsible for the kinase function of the protein. PI3K 
plays a very important role in the PI3K/AKT signaling 
pathway, one of the major pathways implicated in thyroid 
carcinoma. As part of this signaling pathway, PI3K helps 
regulate cell proliferation, motility, adhesion, and cell cycle 
progression. The pathway begins with signals transmitted 
from the environment to the inside of the cell through 
RTKs. These RTKs then engage PI3K, recruiting the protein 
to the cell membrane and generating phosphatidylinositol-
3,4,5-triphosphate (PIP3). PIP3 acts as a second messenger, 
recruiting protein kinases phosphoinositide-dependent 
protein kinase 1 (PDK1) and AKT to the membrane. Once 
activated via phosphorylation, these kinases target their 
downstream effectors, producing concomitant changes to 
cell growth and differentiation. This pathway is regulated 
by the PTEN lipid phosphatase, which dephosphorylates 
PIP3 and thus shuts off the PI3K/AKT pathway (27).
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The PI3K pathway is frequently activated in thyroid 
carcinoma and studies have reported the overexpression 
of PIK3CA in FTC and ATC. The most common PIK3CA 
mutations observed with oncogenic effects tend to cluster 
around exons 9 and 20. These mainly somatic mutations 
result in the constitutive activation of PI3K. Consequently, 
this leads to overactivation of the PI3K/AKT pathway and 
thyroid tumorigenesis. Genetic alterations have been found 
in all differentiated stages of thyroid carcinoma. However, 
it seems to be the most frequent in ATC, occurring in 
about 24% of ATC cases. Given the occurrence of PIK3CA 
mutations in all stages of thyroid carcinoma, it supports the 
implication of the PI3K/AKT signaling pathway in both the 
initiation and progressive dedifferentiation of the disease 
(27,28,29).
PTEN
PTEN, phosphatase and tensin homolog, encodes a 
phosphatase enzyme found in almost all tissues in the 
body. Located on chromosome 10q23.3, PTEN plays an 
important role in the PI3K/AKT pathway. Once activated 
via phosphorylation, PTEN works to terminate the signaling 
pathway through its phosphatase activity. It converts PIP3 
into PIP2and shuts off the PI3K/AKT pathway and reduces 
the recruitment of kinases PDK1 and AKT. As a result, this 
protein helps regulate cell proliferation and differentiation 
(28,29).
A tumor suppressor gene, PTEN is found mutated 
frequently in thyroid tumors. Point mutations, deletions, 
and promoter methylation in PTEN have been reported in 
thyroid carcinoma, particularly undifferentiated ones like 
ATC. Overall, studies have shown that PTEN inactivation is 
a critical step in thyroid tumor progression. This is evident 
in the fact that PTEN is downregulated or absent in highly 
malignant thyroid carcinoma like ATC, though mutations 
have been found in more differentiated forms. PTEN 
downregulation has been reported in about 37% of FTCs. 
Ultimately, this inactivation results in the overactivation of 
the PI3K/AKT signaling pathway, resulting in rampant cell 
proliferation (28,29,30). 
PTEN mutations tend to be most frequent in ATC, with an 
occurrence in about 15% of cases. Germline mutations of 
PTEN is also a leading cause of CS, a disorder that can result 
in benign and malignant tumors. Individuals with CS have 
a 10% risk of developing thyroid cancer. This association 
between CS and PTEN further supports its role in thyroid 
tumorigenesis (27,29,30,31).
TSHR 
The TSHR gene, located on chromosome 14q31, encodes 
the TSHR. This G protein-coupled receptor spans the 
membrane of follicular cells in the thyroid. Once activated 
by thyroid stimulating hormone (TSH), TSHR produces 
corresponding effects in the cell via second messengers 
like cAMP. This intracellular signaling plays an important 
role in thyroid cell proliferation and maintenance of thyroid 
function (Figure 4). Deregulation of TSHR seems to play an 
important role in thyroid carcinogenesis (20).
Studies have shown an association between high levels 
of TSH and the development of thyroid nodules. The 
overactivation of TSHR, whether through activating 
mutations in TSHR or GNAS, has also been shown to lead 
to hyperfunctional FTA. However, these tumors are rarely 
malignant, suggesting that TSHR could serve a dichotomous 
role - protecting against malignancy of thyroid tissue but 
also promoting carcinogenesis likely when activated by 
other oncogenic alterations. Mouse models have shown 
that TSHR is required for thyroid carcinogenesis. It is 
still uncertain whether this supports TSHR’s role in the 
initiation of thyroid carcinoma or it is simply due to the 
TSHR-dependent generation of thyroid cells from which 
carcinogenesis initiates (20,32,33). 
Epigenetics has shown to play an integral part in the 
role of TSHR in thyroid carcinoma. Hypermethylation of 
the TSHR promoter has been frequently found in thyroid 
carcinoma, while it is unmethylated in normal and benign 
thyroid tumors. This epigenetic silencing is most prevalent 
in PTC, with a frequency of 34-59%. Epigenetic silencing via 
hypermethylation is also prevalent in more undifferentiated 
forms of thyroid carcinoma. Studies have also shown 
a strong association with B-RAF mutations in PTC. This 
relationship supports the theory that TSHR silencing is a 
secondary genetic event in thyroid carcinogenesis and not 
essential for the initiation of thyroid carcinoma (32,33). 
The silencing of TSHR not only contributes to the 
development of thyroid carcinoma, but it desensitizes the 
thyroid tumors to radioiodine therapy through its interaction 
with sodium iodide symporter (NIS) in iodide uptake. The 
suppression of TSHR hinders the cancer cells’ ability to 
concentrate iodine. Though no silencing mutations have 
been found thus far, it seems that methylation of TSHR 
serves as a marker for thyroid malignancy (33). 
TG 
The TG gene located on chromosome 8q24, encodes the 
prohormone TG. This protein, found in thyroid follicular 
cells, acts as a precursor for the thyroid hormones, serving 
as the matrix from which they are produced. It acts as a 
protein storehouse and when the thyroid hormones are 
needed, TG is altered and broken down to release the 
needed hormones. Tyrosine residues on the TG protein 
are iodinated, priming the protein for modification into 
the thyroid hormones T3 and T4 (Figure 4). The synthesis 
of TG is regulated by TSH, with TSH serving to stimulate 
production (34). 
Mutations in TG have been reported in thyroid carcinoma. 
They tend to be more frequently found in differentiated 
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thyroid carcinomas, like PTC. The majority of PTCs with 
a mutation in TG tend to also carry a mutation in one 
of the genes in the MAPK signaling pathway. Though 
rarely mutated, TG does seem to contribute to the 
malignancy of the cancer. As the cancer dedifferentiates, 
the expression of TG seems to decrease, with it becoming 
absent in ATC. These genetic changes do not seem to 
be sufficient to initiate thyroid carcinogenesis, but 
the hormonal imbalance produced seems to aid in its 
progression (34,35). 
Changes in TG are more commonly associated with 
dyshormonogenesis, occurring with a frequency of 25%. 
Individuals with the disorder tend to develop goiters, often 
due to chronic stimulation by TSH. Studies have shown that 
individuals with these dyshormonogenic goiters and TG 
mutations have an increased risk of developing aggressive 
forms of thyroid carcinoma. 
TG also serves as a tool for monitoring thyroid cancer 
recurrence and metastasis after treatment and 
thyroidectomy. Serum TG levels are carefully monitored and 
upon stimulation by TSH, if levels rise too high it serves as 
a strong indicator of metastases. Such an association helps 
support the role of TG dysregulation in the development of 
thyroid carcinoma (35,36,37,38).
PAX8/PPARγ 
A chromosomal rearrangement found in thyroid carcinoma 
is that between the genes PAX8 and PPARγ, PAX8 
encodes a transcription factor that is essential for normal 
thyroid development. The PPARγ gene encodes a nuclear 
receptor part of the PPAR subfamily. This receptor forms 
heterodimers with retinoid X receptors and helps regulate 
the transcription of several genes, playing a major role in 
adipogenesis and lipid metabolism (3,39). 
This rearrangement is the result of a translocation between 
chromosome regions 2q13 and 3p25. Highly expressed 
in thyroid follicular cells, it seems this fusion protein plays 
a role in thyroid tumorigenesis. The exact mechanism is 
still unknown. Some studies show that PAX8/PPARγ has 
a dominant negative effect on wild type PPARγ, which is 
believed to act as a tumor suppressor. The fusion protein 
contains the transcriptional regulatory domains of both 
proteins. As a result, it is capable of modulating their 
respective downstream pathways, usually targeting PAX8-
responsive promoters (39,40).
PAX8/PPARγ is most frequently found in FTCs, with 
an occurrence rate of about 30%, and occurs rarely 
in the follicular variant of PTC. The presence of this 
rearrangement has no major impact on the prognosis of 
thyroid carcinoma. Though still much remains unknown 
about this chromosomal rearrangement, evidence points to 
its potential as an oncoprotein and genetic driver of thyroid 
carcinoma (4,39,40).
IGF2BP3/IMP3
The IGF2BP3 gene is located on chromosome 7p11.2, 
and encodes for the insulin-like growth factor-2 (IGF-
2) mRNA-binding protein 3. IGF2BP3 is a RNA-binding 
protein consisting of two RNA-recognition motifs in its 
N¬-terminal part and four KH homology domains in the 
C-terminal region. Its primary function is as a translational 
activator of the IGF-2 gene, while also functioning as a 
post-transcriptional regulator of cell proliferation, and 
differentiation during embryogenesis. It is important to note 
that IGF2BP3 is a member of the highly conserved IGF2BP 
family of mRNA-binding proteins along with IGF2BP1 and 
IGF2BP2. As a member of the IGF2BP family IGF2BP3 shares 
a high amount of similarity to the other three members at 
the amino acid level but differs in terms of its expression. 
IGF2BP3 is abundantly found in all tissues during embryonic 
stage, but it’s expression in normal mature tissue is confined 
to the placenta and reproductive tissue (41,42,43).
IGF2BP3 has been the member of the IGF2BP family to 
be most associated with various cancer types such as 
lung, ovarian, pancreatic, and colorectal. Its role in tumor 
progression has been suggested to be by promoting cell 
growth, proliferation and resistance to ionic radiation via 
an IGF-2 dependent manner. Recent studies have found 
IGF2BP3 to play a role in increasing the invasive potential 
of tumor cells in vitro (42,43).
Due to the high transcript levels of IGF2BP3 in neoplastic 
cells and near undetectable presence in most adult tissue, 
it’s been suggested as a potential biomarker. Through the 
use of immunoassays, its expression has been exclusively 
observed in malignant thyroid cancers of follicular origin, 
with a small portion of classical PTC, and was observed in 
59% of cases for poorly differentiated thyroid carcinoma 
variants. However, through the use of reverse transcription 
polymerase chain reaction (RT-PCR) and qRT-PCR assay, 
it was demonstrated that IGF2BP3 was overexpressed in 
thyroid carcinoma tissue when compared to benign thyroid 
lesions. IGF2BP3’s overexpression in thyroid carcinoma, its 
near undetectable levels in adult tissue, and its potential to 
distinguish between benign and malignant tissue make it 
an excellent candidate for the thyroid cancer sequencing 
panel (41,44,45,46).
KRT7/KRT20
The KRT7 and KRT20 genes both belong to the keratin 
gene family, which consists of 54 functional genes. The 
KRT7 gene can be found in type 2 cluster on chromosome 
12, while the KRT20 gene is located in the type 1 cluster 
on chromosome 17. The protein products of these genes 
are subdivided into type 1 and type 2 based on their 
molecular weights. KRT7 and KRT 20 both encode for 
cytokeratin proteins that are intermediate filament forming 
proteins exclusively found in epithelial tissue. The filaments 
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are formed from the heterodimer pairing of type 1 and 
type 2 cytokeratin proteins in equimolar amounts. The 
intermediate filaments created by cytokeratin proteins 
aid in forming the structural framework of epithelial cells, 
regulate cell size, growth, division, as well as protection 
against mechanical stressors (46,47).
Adenocarcinomas compromise the largest group of 
human epithelial malignancies and can occur in different 
organs. KRT7 and KRT20 along with the other members 
of the keratin gene family have been utilized as diagnostic 
markers to determine the origin tissue, due to the 
characteristic cell-type, differentiation and functional 
status-dependent expression pattern of cytokeratin in 
epithelial cells. In most adenocarcinomas, the expression 
levels of KRT7 and KRT20 are variable and thus are often 
screened for together (47).
Current literature on KRT7/KRT20 combined screening of 
thyroid neoplasms is scarce. Almost all thyroidal tumor’s 
expression levels for KRT7 and KRT20 have been found to 
be positive and negative, respectively. In fact, one study 
looked into the immunohistochemical profile of 43 different 
types of primary and metastatic thyroid neoplasms. They 
found that excluding anaplastic carcinomas, 79% of thyroid 
tumors and 94% of metastatic thyroid carcinoma cases 
reacted positively with the antibody. While the study found 
a positive result for KRT7, none of the thyroid tumors or 
their metastases reacted at all to the KRT20 antibody. A 
second retrospective study examined 153 thyroid carcinoma 
samples for KRT7/KRT20 immunohistochemically, and they 
found that all papillary carcinomas, follicular carcinomas, 
and medullary carcinomas were KRT7 positive and KRT20 
negative. Due to the fact that KRT7 has been positively 
stained in almost all thyroid neoplasms while KRT20 has 
consistently been undetectable, KRT7 and KRT20 are 
excellent candidates for the thyroid cancer sequencing 
panel (48,49,50).
TP53 
The gene TP53 encodes tumor protein p53, located on 
chromosome 17p13.1. This protein is a nuclear transcription 
factor that functions as a tumor suppressor. P53 contains 
three functional domains: a transactivation domain, a DNA 
binding domain, and an oligomerization domain. In the 
nucleus, it binds directly to DNA in order to help prevent 
mutated or damaged DNA from dividing. The protein 
either activates other genes to fix any damages or triggers 
cell cycle arrest and apoptosis (Figure 5). As a result, this 
protein plays a crucial role in regulating cell division and 
preventing tumor formation (51).
Any impairment in the function of TP53 can lead to 
destabilization of the genome and an accumulation of 
mutations. Most changes involve point mutations in exons 
5-8, deletions, or inactivation through indirect mechanisms 
such as methylation. The now inactivated TP53 protein 
becomes unable to bind to DNA and thus is unable to 
repair damages that arise in the DNA. The protein, as well 
as damages to the DNA, just accumulates in the nucleus. 
These type of changes are usually restricted to poorly 
differentiated thyroid cancers like ATC, reportedly occurring 
in 60% of cases (8,51).
TP53 exhibits tremendous oncogenic potential, as it is 
mutated in about 50% of all human cancers. However, 
inactivating mutations of TP53 are found in only about 10% 
of thyroid carcinomas overall. In well differentiated thyroid 
carcinomas, TP53 mutations have a reported relevance 
ranging from 0 to 25%. Though it seems other mechanisms 
of TP53 inactivation play a role in thyroid carcinogenesis, 
as p53 protein is more commonly overexpressed with a 
frequency of 11-59% (51,52). 
CALCA
CALCA (CALCA-1) gene is a member of the calcitonin 
gene family consisting of four known genes, CALCA-1, 
CALCA-2, CALCA-3, and CALCA-4 all containing 
nucleotide sequence homologies. The CALCA gene 
located on chromosome 11 encodes for two separate 
peptide hormones. This gene consists of six exons in 
which exon 4 and 5 contain the sequences for the 
calcitonin and calcitonin gene related peptide (α-CGRP), 
respectively. Post-transcriptional processing of the CALCA 
gene in thyroid C cells and neural tissue results in tissue 
specific production of calcitonin and α-CGRP mRNAs. CT 
is a 32 amino-acid peptide hormone with tissue specific 
functional roles in the central nervous, skeletal, renal 
and gastrointestinal systems. However, CT’s major role 
is in calcium and phosphate metabolism. CT modulates 
calcium levels by binding with CT receptors to inhibit 
osteoclast motility. All of CT’s activities occur through 
its binding to the calcitonin receptor, which couples its 
binding to the activation of cAMP and PKC signaling 
pathways (53,54,55).
Due to the uncharacteristically high concentrations of 
calcitonin, serum CT is classically used as a diagnostic 
biomarker for MTC. Studies have demonstrated that 
preoperative serum CT levels can be strong predictors for 
tumor size and remission. Preoperative CT serum levels above 
1000 pg/mL correspond to 25.0 mm tumor sizes, while levels 
below 100 pg/mL were associated with 3.0 mm tumor size. 
Distant metastases are the main cause of death in patients 
diagnosed with MTC. Metastasis is initially presented in 
50% of MTC cases. Postoperative serum CT levels are an 
important procedure in screening for biochemical remission. 
CT doubling times have been found to be associated with 
progressive or stable disease in 80% of patients. In a study 
they found doubling times shorter than 25 months to have 
a 94% predictive value of progressive disease along with a 
predictive value of 86% for patients with a doubling time 
longer than 24 months (53,56,57,58,59).
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CALCA detection studies and procedures involve detection of 
this peptide from blood serum. There are limitations to these 
assays due to needing stimulation tests, and possible intra-
assay variation. Some research has found that detection of 
CALCA gene transcripts presented higher clinical sensitivity, 
specificity, and positive predictive values of 86.67, 97.06, and 
92.86%, respectively. In addition to these promising results 
their readings mirrored measurements obtainable through 
a pentagastrin stimulation test. Due to its tissue specific 
production and role in preoperative and postoperative 
diagnosing of MTC, CALCA is a viable candidate to include 
in the thyroid cancer mutation panel (53,60).
MET
MET, also known as c-MET, encodes a proto-oncogene 
that is located on chromosome 7q31. A member of the 
RTK family, the MET receptor elicits its effects by binding 
to its ligand, hepatocyte growth factor (HGF). Once bound 
to HGF, the MET receptor dimerizes and thus becomes 
activated and helps promote cell proliferation, survival, and 
motility. These effects are largely the result of activation 
of MAPK and PI3K pathways through MET signaling. This 
process is tightly regulated and any disruption can result in 
tumorigenesis (61).
In thyroid carcinoma, what is most commonly seen 
is a deregulation of MET, most commonly in PTC. 
This deregulation often involves overactivation or 
overexpression of MET, which has been shown to 
promote tumor growth. This activation can be the 
result of activating point mutations often located in the 
tyrosine kinase domain, or paracrine signaling due to 
increased sensitivity to HGF. The altered MET gene acts 
as a mitogenic factor and helps promote cell motility and 
invasion (61,62). 
Expression levels of MET tend to be low and tightly 
regulated in normal thyroids. However, it is amplified in 
75% of PTCs, as well as in many FTCs. This overexpression 
seems to be secondary to other driver mutations like RAS 
and B-RAF. Despite its secondary role, evidence points to 
increased MET signaling having a significant role in the 
pathogenesis of thyroid carcinoma (62,63,64).
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Figure 5. P53 pathway
*Signals of cellular stress, such as DNA damage, triggers activation of p53. Once activated, this nuclear transcription factor travels to the nucleus and binds to DNA, increasing 
expression of target genes involved in DNA repair and triggering apoptosis. p53 activity also induces expression of MDM2 as well. MDM2 serves to regulate p53 activity, 
inhibiting transcription of p53 and promoting its degradation. Overall, this pathway functions as an auto-regulatory feedback loop
EIF1AX 
This X-linked gene, located on Xp22.12, encodes the 
eukaryotic translation initiation factor 1A. This particular 
protein is required for the formation of the preinitiation 
complex (PIC). It does so by stabilizing the binding of 
the initiator tRNA (Met-tRNA) with the 40S ribosomal 
subunit and the translation initiation factor eIF2. This is 
an integral step in the translation of mRNA into proteins, 
as it is required for the binding of the PIC to the 5’ end 
of capped mRNA and finding the proper start codon 
(65,66).
Mutations in EIF1AX have been found in both PTC 
and ATC. The most common sites of mutation are the 
N-terminal domain and a C-terminal splice acceptor site 
between exons 5 and 6. The C-terminal mutations seem 
to be specific to thyroid carcinoma. In PTC, it is rare and 
occurs in a mutually exclusive manner, found in only 1-2% 
of tumors. But, it is more frequent in ATC, found in 10% 
of tumors. It seems that these mutations result in an 
overactive EIF1AX, as it has been shown to increase cell 
proliferation (65,66,67,68). 
EIF1AX mutations tend to coexist with RAS mutations and 
other driver mutations of thyroid carcinoma like TP53. This 
co-occurrence tends to be found predominantly in poorly 
differentiated thyroid carcinomas like ATC. This strong 
association suggests that EIF1AX is not sufficient enough 
to transform thyroid carcinoma into a malignant form. 
Mutations in EIF1AX have also been associated with poor 
prognosis in PDCs. The mechanisms of EIF1AX mutation in 
thyroid carcinoma are still unclear, especially in terms of its 
association with RAS mutations (65,66,67,68).
TTF1 
Also known as NK2 homeobox 1, this gene encodes thyroid 
transcription factor 1. The TTF1 protein is expressed in the 
epithelial cells of the thyroid with a heterogeneous distribution. 
As a homeoprotein, it plays an important role in thyroid 
development, cell growth, and differentiation. Essential for 
thyroid organogenesis, TTF1 helps modulate thyroid function 
through its regulation of gene expression in the thyroid, 
activating the transcription of thyroid-specific genes like 
thyroglobulin (TG) and thyroperoxidase (TPO) (69,70).
The mechanisms by which TTF1 contributes to thyroid 
carcinoma still remains unclear. Though the gene is 
expressed in thyroid carcinoma, its level of expression 
becomes reduced as cell dedifferentiation progresses. This 
change in expression could be the result of epigenetic 
silencing, likely achieved through hypermethylation and 
histone H3 modification. As a result, ATC exhibits the lowest 
levels of TTF1. In thyroid carcinoma as a whole it seems 
likely that TTF1’s molecular functions, DNA binding, and 
transcription activation are probably disrupted. That could 
explain why most undifferentiated thyroid carcinomas 
have little to no TG or TPO proteins, both targets of TTF1 
transcription factor activity (41,42,43). 
Germline mutations in TTF1 have also been shown to 
play a role in thyroid carcinoma, specifically in PTC. These 
mutations seem to promote cell proliferation as well as 
activate signaling pathways like PI3K/AKT. The germline 
mutations observed in TTF1 have also been associated with 
multinodular goiter. This provides further evidence of a 
progression from a benign multinodular goiter to malignant 
thyroid carcinoma, such as PTC. Given the important role 
TTF1 plays in maintaining thyroid architecture and function, 
it is not surprising that any abnormalities in the gene and 
its product contribute to the development of thyroid 
carcinoma (70,71,72). 
PTH 
The PTH gene encodes a member of the parathyroid family 
of proteins and is located on chromosome 11p15.3. This 
particular protein binds to the parathyroid hormone receptor 
and helps regulate blood calcium and phosphate levels in 
the body. Abnormal levels of PTH tend to be associated with 
parathyroid diseases, like hyperparathyroidism. However, 
there is evidence to suggest a possible link between PTH 
and the development of thyroid carcinoma (73). 
Primary hyperparathyroidism (PHPT) is a disease that has 
been associated with thyroid carcinoma. PHPT results 
from an excessive secretion of PTH, which causes an 
elevation of calcium in the blood. The most common form 
of thyroid carcinoma associated with PHPT is a hereditary 
form of MTC known as multiple endocrine neoplasia 
type 2A (MEN2A). Carriers of the MEN2A gene with a 
mutation at codon 634 concomitantly suffer from PHTP 
with a frequency of 10-25%. Such an association provides 
evidence to support the role of PTH dysregulation in 
thyroid carcinoma (73,74). 
Associations between non-medullary thyroid carcinoma 
and PHPT have also been reported. With rates ranging from 
2-10%, thyroid malignancy seems to coexist with PHPT, 
albeit not frequently. A strong relationship has also been 
found between ionizing radiation and the simultaneous 
development of PHPT and thyroid carcinoma. PTH may 
also contribute to the development of thyroid carcinoma 
through chromosomal rearrangement with PAD1. This 
rearrangement results in an overexpression of cyclin D1 
and thus an increase in cell proliferation. Though some 
changes to PTH may be the result of metastatic invasion 
of the parathyroid by thyroid carcinoma, the evidence 
available shows that the role of PTH in thyroid malignancy 
overall warrants further investigation (75,76,77). 
SCL5A5
The SCL5A5 gene encodes the NIS. NIS is a glycosylated 
protein with 13 trans-membrane domains and functions 
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to actively transport one I- and two Na+ ions from the 
sodium ion gradient established by the Na+/K+ ATPase. 
NIS expression at both the transcriptional level and 
posttranscriptional level is modulated by the effects of TSH. 
TSH causes elevated levels of endogenous cAMP in the 
thyroid cells. These cAMP levels play a role in stimulating 
several cis-regulatory elements found in the promoter and 
upstream enhancer sequences on the SCL5A5 gene on 
chromosome 19 (78,79).
The SCL5A5 gene contains an upstream enhancer sequence 
(NUE) reported to have both a Pax-8, and cAMP-response 
element (CRE) binding sites. Pax-8 and cAMP-response 
element modulator (CREM) transcription factors bind to 
these cis-elements on the upstream enhancer via cAMP-
signaling pathways. These elements are stimulated through 
cAMP activation of protein kinase-A (PKA) dependent 
pathways in thyroid cells. PKA dependent activation 
phosphorylates basic-leucine zipper (B-ZIP) proteins, 
CREM, activating transcription factor-1 (ATF-1), and cAMP-
response element binding protein (CREB). Studies have 
found that the binding of these transcription factors are 
necessary for the NUE’s cAMP induced activity on thyroidal 
responsive genes such as TPO, TG, TSHR, and NIS (Figure 6). 
While CREB binding is important for SLC5A5 transcriptional 
regulation, full SLC5A regulation is not established without 
PAX-8 binding. TSH binding increases the expression and 
translocation of the anti-oxidative stress factor Ref-1. Ref-
1 is a nuclear enzyme that reduces Pax-8 and mediates 
its binding to the NUE sequence. Impaired translocation 
of this nuclear enzyme has been reported in anaplastic, 
papillary cell lines as well as in thyroid cancer tissue. TSH 
also plays a role in the posttranscriptional regulatory role in 
the transport of NIS to the basolateral membrane (78,79).
While no somatic mutations to NIS have yet been identified, 
alterations in other genes have been found to be associated 
with NIS impairment in differentiated thyroid cancers. 
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Figure 6. Sodium iodide symporter gene signaling
*The sodium Iodide symporter is a transmembrane protein that plays a crucial role in the uptake of iodine by thyroid cells. The SCL5A5 gene is regulated by the activity of 
TSH on the sodium iodide symporter upstream enhancer sequence (NUE). In this pathway TSH binding to TSHR stimulates an increase in cyclic AMP (cAMP) levels in the cell. 
Elevated levels of cAMP lead to the activation of protein kinase-A (PKA) dependent p38/MAPK and PKA-cAMP-response element binding protein (CREB) pathways. The p38/
MAPK pathway leads to the recruitment of basic-leucine zipper transcription factors ATF1, and cAMP-response modulator to the nucleus. In the nucleus these transcription 
factors bind to the cAMP-response element binding sites in the NUE and activating the SCL5A5 gene. PKA can also directly phosphorylate the cAMP-CREB to directly regulate 
cAMP responsive genes such as TSHR, and SCL5A5. Full activation of the SCL5A5 gene is not reached until the PAX-8 transcription factor bindings to the NUE promoter site. 
TSH signaling upregulates the transcription and nuclear translocation of the oxidative stress factor Ref-1. Ref-1 activates and recruits PAX-8 to bind to the NUE promoter site, 
leading to full SCL5A5 gene activity. Inhibition of SCL5A5 activity can also occur due to the elevated levels of cAMP. These elevated levels can trigger activation of the PI3K 
signaling pathway leading to the downregulation of the SLC5A5 gene
B-RAFV6000E mutations reduce NIS mRNA expression by 
inducing the secretion of transforming growth factor-β 
(TGF-β). TGF-β acts via the SMAD signaling pathway in an 
MEK/ERK independent pathway. RET/PTC rearrangement 
impairs the activity of PAX-8 and PKA. Reducing the activity 
of these two proteins has been demonstrated to reduce 
recruitment of B-ZIP proteins and reduced binding to the 
PAX-8 and CRE elements in NUE (79,80,81).
NIS expression has been reported to be reduced in 
differentiated thyroid carcinomas. One study found reduced 
NIS mRNA expression in PTC tissue samples when compared 
to adjacent normal thyroid tissue. NIS expression was also 
found to be generally reduced in benign thyroid nodules 
compared with adjacent normal tissue, but to a lesser 
extent than in PTC tissue samples. It has also been reported 
that NIS gene expression is impaired in hypo-functioning 
thyroid tumors when compared to normal thyroid tissue. 
Quantification of SCL5A5 mRNA levels should be added to 
the classical prognostic factors currently used to predict the 
outcomes of patients with differentiated thyroid cancer. 
SCL5A5 is an excellent candidate for the thyroid cancer 
mutation panel (82,83,84).
Conclusion
Thyroid carcinoma is the result of an accumulation of 
genetic changes that impact its initiation and progression. 
These genetic alterations, thus, serve as both diagnostic and 
prognostic markers of thyroid carcinoma. ThyroSeq NGS 
allows for the use of small amounts of DNA to test for a 
very broad range of mutations and other genetic alterations, 
helping identify molecular profiles for the different types 
of thyroid carcinoma. The genotyping of thyroid samples 
provides invaluable insight in determining the proper course 
of treatment when faced with a cytologically indeterminate 
thyroid nodule. 
The genetics of thyroid cancer provides us with a greater 
understanding of the pathophysiology of the disease than 
is possible from its cellular morphology. The presence of 
mutations in the molecular pathology profile can not only help 
more accurately determine malignancy in the thyroid nodules 
but help better predict the biology of thyroid carcinoma which 
will have paramount importance to tailor treatment strategies. 
The presence of certain genetic alterations may prove 
indicators of aggressiveness of the cancer and predictors for 
metastasis. As more studies are conducted, and the genomic 
profile of thyroid carcinoma is further elucidated, the utility 
of genomic profiling in the diagnosis and prognostication of 
thyroid cancer will be solidified. 
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